Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) Director Bvf Partners L. P/Il acquired 317,167 shares of the firm's stock in a transaction dated Monday, June 30th. The stock was bought at an average cost of $44.00 per share, for a total transaction of $13,955,348.00. Following the purchase, the director directly owned 2,798,795 shares of the company's stock, valued at approximately $123,146,980. This trade represents a 12.78% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Kymera Therapeutics Trading Up 0.6%
Shares of KYMR stock traded up $0.28 on Friday, reaching $44.81. 240,486 shares of the company's stock were exchanged, compared to its average volume of 632,626. Kymera Therapeutics, Inc. has a 52 week low of $19.45 and a 52 week high of $53.27. The stock has a market capitalization of $2.92 billion, a PE ratio of -14.45 and a beta of 2.18. The company's fifty day simple moving average is $38.46 and its 200 day simple moving average is $35.92.
Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) last released its earnings results on Friday, May 9th. The company reported ($0.82) earnings per share for the quarter, topping analysts' consensus estimates of ($0.92) by $0.10. The business had revenue of $22.10 million for the quarter, compared to analyst estimates of $11.38 million. Kymera Therapeutics had a negative return on equity of 30.11% and a negative net margin of 409.07%. The business's revenue was up 114.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.69) earnings per share. As a group, sell-side analysts predict that Kymera Therapeutics, Inc. will post -2.79 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
KYMR has been the topic of a number of recent analyst reports. Morgan Stanley began coverage on Kymera Therapeutics in a report on Thursday. They set an "overweight" rating and a $70.00 price target on the stock. Bank of America raised Kymera Therapeutics from a "neutral" rating to a "buy" rating and set a $51.00 price target on the stock in a report on Monday, June 2nd. UBS Group decreased their price target on shares of Kymera Therapeutics from $72.00 to $70.00 and set a "buy" rating on the stock in a research note on Tuesday, May 13th. Wall Street Zen upgraded shares of Kymera Therapeutics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, B. Riley upgraded shares of Kymera Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the company from $38.00 to $60.00 in a research report on Tuesday, June 3rd. Two investment analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $59.11.
View Our Latest Research Report on KYMR
Institutional Inflows and Outflows
Institutional investors have recently added to or reduced their stakes in the stock. State of Wyoming purchased a new stake in Kymera Therapeutics in the 4th quarter valued at about $45,000. GF Fund Management CO. LTD. purchased a new stake in shares of Kymera Therapeutics in the fourth quarter valued at approximately $55,000. KBC Group NV boosted its holdings in shares of Kymera Therapeutics by 15.2% in the first quarter. KBC Group NV now owns 2,479 shares of the company's stock valued at $68,000 after purchasing an additional 328 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in Kymera Therapeutics in the first quarter worth approximately $68,000. Finally, Advisors Asset Management Inc. increased its holdings in Kymera Therapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,959 shares of the company's stock worth $136,000 after purchasing an additional 2,230 shares during the period.
About Kymera Therapeutics
(
Get Free Report)
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
Read More

Before you consider Kymera Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kymera Therapeutics wasn't on the list.
While Kymera Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.